Catherine A. Cotter

Catherine A. Cotter

Auto-generated profile, based on publicly available information

Catherine A. Cotter

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JAJeffrey L. Americo
Jeffrey L. Americo
CCCatherine A. Cotter
Catherine A. Cotter
PEPatricia L. Earl
Patricia L. Earl
RLRuikang Liu
Ruikang Liu
BMBernard Moss
Bernard Moss
Current vaccines have greatly diminished the severity of the COVID-19 pandemic, even though they do not entirely prevent infection and transmission, likely due to insufficient immunity in the upper respiratory tract. Here, we compare intramuscular and intranasal administration of a live, replication-deficient modified vaccinia virus Ankara (MVA)–based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike (S) vaccine to raise protective immune responses in the K18-hACE2 mouse model. Using a recombinant MVA expressing firefly luciferase for tracking, live imaging revealed luminescence of the respiratory tract of mice within 6 h and persisting for 3 d following intranasal inoculation, whereas luminescence remained at the site of intramuscular vaccination. Intramuscular vaccination induced S-binding–Immunoglobulin G (IgG) and neutralizing antibodies in the lungs, whereas intranasal vaccination also induced Immunoglobulin A (IgA) and higher levels of antigen-specific CD3 + CD8 + IFN-γ + T cells. Similarly, IgG and neutralizing antibodies were present in the blood of mice immunized intranasally and intramuscularly, but IgA was detected only after intranasal inoculation. Intranasal boosting increased IgA after intranasal or intramuscular priming. While intramuscular vaccination prevented morbidity and cleared SARS-CoV-2 from the respiratory tract within several days after challenge, intranasal vaccination was more effective as neither infectious virus nor viral messenger (m)RNAs were detected in the nasal turbinates or lungs as early as 2 d after challenge, indicating prevention or rapid elimination of SARS-CoV-2 infection. Additionally, we determined that neutralizing antibody persisted for more than 6 mo and that serum induced to the Wuhan S protein neutralized pseudoviruses expressing the S proteins of variants, although with less potency, particularly for Beta and Omicron.

9 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
RLRuikang Liu
Ruikang Liu
JAJeffrey L. Americo
Jeffrey L. Americo
CCCatherine A. Cotter
Catherine A. Cotter
PEPatricia L. Earl
Patricia L. Earl
NENoam Erez
Noam Erez
BMBernard Moss
Bernard Moss
Significance: Vaccines are required to control COVID-19 during the current pandemic and possibly afterward. Recombinant nucleic acids, proteins, and virus vectors that stimulate immune responses to the SARS-CoV-2 S protein have provided protection in experimental animal and human clinical trials, although questions remain regarding their ability to prevent spread and the duration of immunity. The present study focuses on replication-restricted modified vaccinia virus Ankara (MVA), which has been shown to be a safe, immunogenic, and stable smallpox vaccine and a promising vaccine vector for other infectious diseases and cancer. In a transgenic mouse model, one or two injections of recombinant MVAs that express modified forms of S inhibited SARS-CoV-2 replication in the upper and lower respiratory tracts and prevented severe disease.

27 March 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
CJCatherine Jacob-Dolan
Catherine Jacob-Dolan
DTDarren Ty
Darren Ty
DHDavid Hope
David Hope
KMKatherine McMahan
Katherine McMahan
JLJinyan Liu
Jinyan Liu
DBDan H. Barouch
Dan H. Barouch
The 2022–2023 mpox outbreak triggered vaccination efforts using smallpox vaccines that were approved for mpox, including modified vaccinia Ankara (MVA; JYNNEOS), which is a safer alternative to live replicating vaccinia virus (ACAM2000). Here, we compare the immunogenicity and protective efficacy of JYNNEOS by the subcutaneous or intradermal routes, ACAM2000 by the percutaneous route, and subunit Ad35 vector–based L1R/B5R or L1R/B5R/A27L/A33R vaccines by the intramuscular route in rhesus macaques. All vaccines provided robust protection against high-dose intravenous mpox virus challenge with the current outbreak strain, with ACAM2000 providing near complete protection and JYNNEOS and Ad35 vaccines providing robust but incomplete protection. Protection correlated with neutralizing antibody responses as well as L1R/M1R- and B5R/B6R-specific binding antibody responses, although additional immune responses likely also contributed to protection. This study demonstrates the protective efficacy of multiple vaccine platforms against mpox virus challenge, including both current clinical vaccines and vectored subunit vaccines.

27 March 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
CCCatherine A. Cotter
Catherine A. Cotter
JAJeffrey L. Americo
Jeffrey L. Americo
PEPatricia L. Earl
Patricia L. Earl
BMBernard Moss
Bernard Moss
SARS-CoV-2 vaccines prevent severe disease but are less efficient in averting infection and transmission of variant strains, making it imperative to explore ways of enhancing protection. Use of inbred mice expressing the human SARS-CoV-2 receptor facilitates such investigations. We employed recombinant MVAs (rMVAs) expressing modified S of several SARS-CoV-2 strains and compared their ability to neutralize variants, bind S proteins and protect K18-hACE2 mice against SARS-CoV-2 challenge when administered intramuscularly or intranasally. The rMVAs expressing Wuhan, Beta and Delta S induced substantial cross neutralizing activities to each other but very low neutralization of Omicron; while rMVA expressing Omicon S induced neutralizing antibody predominanly to Omicron. In mice primed and boosted with rMVA expressing the Wuhan S, neutralizing antibodies to Wuhan increased after one immunization with rMVA expressing Omicron S due to original antigenic sin, but substantial neutralizing antibody to Omicron required a second immunization. Nevertheless, monovalent vaccines with S mismatched to the challenge virus still protected against severe disease and reduced the amounts of virus and subgenomic RNAs in the lungs and nasal turbinates, though not as well as vaccines with matched S. Passive transfer of Wuhan immune serum with Omicron S binding but undetectable neutralizing activity reduced infection of the l–ungs by Omicron suggesting additional effector functions. Notably, there was less infectious virus and viral subgenomic RNAs in the nasal turbinates and lungs when the rMVAs were administered intranasally rather than intramuscularly and this held true for vaccines that were matched or mismatched to the challenge strain of SARS-CoV-2.

10 June 2026 in Nature Microbiology
Verified
Journal Article
Open access
HYHUIBIN YU
HUIBIN YU
WRWolfgang Resch
Wolfgang Resch
CCCatherine A. Cotter
Catherine A. Cotter
WXWei Xiao
Wei Xiao
TKTase Karamanolis
Tase Karamanolis
BMBernard Moss
Bernard Moss
Poxviruses rely on a conserved multiprotein entry–fusion complex, providing numerous potential antibody targets, although the immunogenicities of only a few have been analysed. Here we tested the ectodomains of ten orthopoxvirus entry–fusion complex proteins in rabbit and mouse immunization experiments and determined that six induce neutralizing antibodies. Focusing on the apical A16/G9 heterodimer, we show that it induces antibodies that prevent vaccinia virus (VACV) entry, cross-neutralize cowpox virus (CPXV) and monkeypox virus (MPXV), and protect mice against lethal challenge infections with VACV and CPXV. However, antibodies to A16/G9 had limited detection following infections with attenuated or virulent VACV, CPXV or MPXV, but were robustly induced upon immunization with recombinant VACVs secreting G9 or that have deletions of the genes encoding the viral fusion suppressor A56/K2 complex, which specifically binds A16/G9. Our work identifies previously unrecognized immunogens for incorporation into recombinant vaccines and characterizes a mode of immune evasion via the A56/K2 complex.